The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy

Launched by BEIJING SHIJITAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY · Dec 6, 2022

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18-65, female;
• • Pathological biopsy confirmed invasive ductal carcinoma;
• • Karnofsky Performance Status (KPS)≥ 60, expected survival ≥4 months;
• • Locally advanced breast cancer (HER2-positive disease and TNBC, ≥cT1c or ≥cN0； HER2-negative，HR positive disease，≥cT2 or ≥cN1；Large primary tumor relative to breast size in a patient who desires breast conservation) ;
• • According to the RECIST1.1 standard, at least one measurable lesion exists;
• Exclusion Criteria:
• • Pregnant or lactating women;
• • Left ventricular ejection fraction less than 50%;
• • History of malignant tumor and concurrent occurrence of other tumors;
• • Serious medical pathology, such as congestive heart failure; unstable angina; uncontrolled high risk arrhythmias, and other serious illness or medical condition that may interfere with the study;
• • Refuse to participate in the study.

Trial Officials